The association between preconception body mass index and subfertility among Hispanic and non-Hispanic women: A cross-sectional study from Utah's Pregnancy Risk Assessment Monitoring System survey (2012-2015)
To investigate the association between pre-pregnancy body mass index (BMI) and subfertility within a population-based cohort, exploring Hispanic ethnicity as a potential effect modifier.
Methods
We used cross-sectional study data from the Utah Pregnancy Risk Assessment Monitoring System from 2012-2015. Relationships between maternal pre-pregnancy BMI and subfertility were evaluated via Poisson regression models with robust error variance, accounting for the stratified survey sampling. Preconception BMI was analyzed continuously and categorically. Women's subfertility was defined via self-report in two ways: 1) time trying to achieve pregnancy; and 2) report of using fertility-related drugs/medical procedures.
Results
The median age was 27.0; 18.8% were obese, and 15.9% were Hispanic. Women with preconception obesity (BMI>30kg/m(2)), compared to normal weight women (18.4kg/ m(2)<BMI<25kg/m(2)) had a 1.85 (95% CI 1.43, 2.38) higher adjusted prevalence ratio (aPR) for having subfertility defined by time trying and a 1.73 (95% CI 1.20, 2.32) higher aPR for receiving fertility-enhancing drugs/medical procedures. Continuous models indicated a linear relationship between BMI and subfertility (aPR 1.04, 95% CI 1.03, 1.06 for time trying; and 1.06, 95% CI 1.03, 1.10 for receiving fertility-enhancing drugs/medical procedures).
Conclusions
Obese women, but not underweight or overweight women, reported higher subfertility than normal-weight women. Findings among this cohort of at-risk new mothers, oversampled on low education and birth weight and comprised of higher than the national average of Hispanics, indicated a dose-response relationship between obesity and subfertility.
Implications
Our findings highlight the importance of population-oriented obesity prevention for at-risk women with intentions to conceive.
preconception BMI subfertility association, body mass index fertility outcomes, obesity subfertility risk, Hispanic ethnicity fertility outcomes, overweight preconception fertility, PRAMS subfertility data, population-based BMI fertility study, weight management preconception care, BMI ethnic modifier fertility, pre-pregnancy obesity reproductive outcomes
PMID 32914149 32914149 DOI 10.3390/ijerph17103449 10.3390/ijerph17103449
Cite this article
Hu, Q., Lee, J., Nelson, J., Harris, M., Ess, R. H., Rogers, C. R., Sanders, J., VanDerslice, J., Stanford, J. B., & Schliep, K. C. (2020). The association between preconception body mass index and subfertility among Hispanic and non-Hispanic women: A cross-sectional study from Utah's Pregnancy Risk Assessment Monitoring System survey (2012-2015). *The Utah women's health review*, *2020*(10). https://doi.org/10.3390/ijerph17103449
Hu Q, Lee J, Nelson J, Harris M, Ess RH, Rogers CR, et al. The association between preconception body mass index and subfertility among Hispanic and non-Hispanic women: A cross-sectional study from Utah's Pregnancy Risk Assessment Monitoring System survey (2012-2015). Utah Womens Health Rev. 2020;2020(10). doi:10.3390/ijerph17103449
Hu, Q., et al. "The association between preconception body mass index and subfertility among Hispanic and non-Hispanic women: A cross-sectional study from Utah's Pregnancy Risk Assessment Monitoring System survey (2012-2015)." *The Utah women's health review*, vol. 2020, no. 10, 2020.
STUDY QUESTION: Is there a difference in live birth rates at 24 months between infertile women with polycystic ovary syndrome (PCOS) who have normal versus abnormal glucose metabolism?
SUMMARY ANSWER...
The primary objective of polycystic ovarian syndrome (PCOS) treatment is to achieve mono-ovulatory cycles, thereby enabling pregnancy and childbirth. Laparoscopic ovarian drilling (LOD) and transvagin...
Brand KM et al., 2025Women's health (London, England)
Influential guidelines have supported the role of metformin in the management of polycystic ovary syndrome (PCOS) for a number of years. However, regulatory approvals for this therapeutic indication a...
Neblett MF 2nd et al., 2023Journal of assisted reproduction and genetics
PURPOSE: To assess efficacy of adjuvant dexamethasone during letrozole cycles for ovulation induction (OI) in women with letrozole-resistant polycystic ovary syndrome (PCOS).
METHODS: We retrospectiv...